In particular, KEYNOTE-024 showed that in advanced NSCLC patients with no EGFR mutations or no ALK fusion who showed high tumoral PD-L1 expression (≥50%), pembrolizumab seemed to be superior to platinum-based chemotherapy [10]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.